In PCa, the factors such as (i) low gastrointestinal absorption (GIA) can affect drug bioavailability, influencing its effectiveness, (ii) Inhibitors of cytochrome P450 enzymes, particularly CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4, can alter the metabolism of drugs used in PCa treatment, impacting their pharmacokinetics and potentially therapeutic outcomes. The gene discussed is CYP3A4; the disease is posterior cortical atrophy.